934290-80-9

Upstream product

• 271-63-6 7-Azaindole 
• 5798-75-4 Ethyl 4-bromobenzoate 
• 51934-41-9 4-iodobenzoic acid ethyl ester 

Downstream Products

• 934290-81-0 C₁₇H₁₄N₂O₃ 
• 1001014-57-8 1-(4-(1H-pyrrolo[2,3-b]pyridin-1-yl)phenyl)-2-(pyrazin-2-yl)ethanone 
• 1001014-58-9 1-(4-(1H-pyrrolo[2,3-b]pyridin-1-yl)phenyl)-2-(hydroxyimino)-2-(pyrazin-2-yl)ethanone 

Relevant academic research and scientific papers

Iron-catalyzed N-arylation of nitrogen nucleophiles

(Chemical Equation Presented) Easy does it! A simple procedure for the N-arylation of nitrogen-containing heterocycles and primary amides relies on a catalyst formed in situ from inexpensive and environmentally benign FeCl 3 and a diamine ligand. The cross-coupling reaction with aryl halides provides N-arylated compounds in high yields (see scheme; R = H, Cl, Me, OMe, CO2Et, F, CF3).

NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds having a xanthine oxidase inhibitory effect and an uricosuric effect and pharmaceutical compositions comprising the same as an active ingredient. That is, the present invention relates nitrogen-containing heterocyclic compounds represented by the following general formula (I): wherein Y1 represents N or C(R4) ; Y2 represents N or C(R5) ; R4 and R5 independently represent an alkyl group, a hydrogen atom etc. ; one of R1 and R2 represents an optionally substituted aryl group, an alkoxygroup or an optionally substituted heterocyclic group; the other of R1 and R2 represents a haloalkyl group, a cyanogroup, ahalogenatometc.; and R3 represents a 5-tetrazolyl group or a carboxy group, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same as an active ingredient.

SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS

The invention pertains to heteroaromatic compounds of the formula I, as defined herein, that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.